Alnylam Pharmaceuticals (ALNY) Competitors $247.66 -3.34 (-1.33%) As of 02:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALNY vs. GILD, VRTX, REGN, BIIB, UTHR, INCY, BMRN, NBIX, EXEL, and EXASShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Exact Sciences Alnylam Pharmaceuticals (NASDAQ:ALNY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings. Do analysts recommend ALNY or GILD? Alnylam Pharmaceuticals presently has a consensus target price of $299.48, indicating a potential upside of 18.55%. Gilead Sciences has a consensus target price of $102.08, indicating a potential downside of 7.50%. Given Alnylam Pharmaceuticals' higher probable upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72Gilead Sciences 0 Sell rating(s) 11 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.72 Which has stronger valuation and earnings, ALNY or GILD? Gilead Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B14.55-$278.16M-$2.17-116.41Gilead Sciences$28.75B4.78$480M$0.37298.25 Do institutionals and insiders believe in ALNY or GILD? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor ALNY or GILD? In the previous week, Gilead Sciences had 32 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 68 mentions for Gilead Sciences and 36 mentions for Alnylam Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.27 beat Alnylam Pharmaceuticals' score of 0.52 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 19 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 48 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ALNY or GILD? Alnylam Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Is ALNY or GILD more profitable? Gilead Sciences has a net margin of 1.67% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Gilead Sciences' return on equity of 31.63% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Gilead Sciences 1.67%31.63%10.38% Does the MarketBeat Community prefer ALNY or GILD? Gilead Sciences received 1334 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. Likewise, 76.83% of users gave Gilead Sciences an outperform vote while only 76.20% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes114376.20% Underperform Votes35723.80% Gilead SciencesOutperform Votes247776.83% Underperform Votes74723.17% SummaryGilead Sciences beats Alnylam Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.98B$7.02B$5.84B$9.20BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-117.412.6016.3214.14Price / Sales14.55320.96461.0479.70Price / CashN/A67.8344.0437.47Price / Book485.816.837.794.78Net Income-$278.16M$138.11M$3.18B$245.88M7 Day Performance-1.49%-0.79%-0.52%-0.90%1 Month Performance-4.67%-0.17%1.80%-0.52%1 Year Performance63.25%-1.82%18.90%16.50% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.5539 of 5 stars$247.66-1.3%$299.48+20.9%+68.7%$32.06B$2.25B-114.132,230Analyst ForecastInsider TradeGILDGilead Sciences4.8073 of 5 stars$104.08-1.8%$101.33-2.6%+52.7%$129.71B$27.12B1,156.4418,000Analyst UpgradeInsider TradeOptions VolumeAnalyst RevisionPositive NewsVRTXVertex Pharmaceuticals4.175 of 5 stars$459.00-0.8%$505.57+10.1%+14.2%$118.21B$9.87B-230.655,400Analyst DowngradeInsider TradeAnalyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.6472 of 5 stars$673.60-0.1%$973.13+44.5%-26.5%$74.02B$14.20B17.6013,450Dividend AnnouncementBIIBBiogen4.7769 of 5 stars$137.33-0.8%$211.96+54.3%-37.5%$20.01B$9.84B12.417,570Analyst ForecastUTHRUnited Therapeutics4.4129 of 5 stars$370.58+0.0%$382.08+3.1%+71.5%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5814 of 5 stars$70.42+0.6%$75.59+7.3%+21.4%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9364 of 5 stars$64.85+0.7%$94.20+45.3%-22.5%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNBIXNeurocrine Biosciences4.9783 of 5 stars$115.02-1.6%$166.90+45.1%-12.5%$11.65B$2.36B34.961,400Analyst DowngradeAnalyst RevisionGap UpEXELExelixis4.6803 of 5 stars$35.00+1.5%$37.24+6.4%+70.1%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeGap UpEXASExact Sciences4.671 of 5 stars$49.31-2.5%$72.76+47.6%-21.1%$9.13B$2.50B-42.146,600Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Exact Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALNY) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
